Assessment of disease activity using a whole-body MRI derived radiological activity index in chronic nonbacterial osteomyelitis.

BACKGROUND: Based on the recently developed ChRonic nonbacterial Osteomyelitis MRI Scoring tool (CROMRIS), we developed a radiological activity index (RAI-CROMRIS) to obtain a quantification of the overall bone involvement in individual patients. METHODS: Whole Body Magnetic Resonance Imaging (WB-MRI) images were scored according to parameters included in the RAI-CROMRIS: bone marrow hyperintensity, signal extension, soft tissue/periosteal hyperintensity, bony expansion, vertebral collapse. These parameters were evaluated for each bone unit yielding a score from 0 to 7 and summed up as RAI-CROMRIS including all bone units. We assessed clinical disease activity using a physician global assessment (PGA) and radiological findings in 76 treatment-naïve patients; 46 of 76 were evaluated at 6 and 12 months after initial WB-MRI. Quantitative variables were compared using the Mann-Whitney U test for unmatched groups and the Wilcoxon signed-rank test for paired groups. Correlation was evaluated using Spearman's rank coefficient (rs). RESULTS: There was a significant correlation between RAI-CROMRIS and PGA (rs = 0.32; p = 0.0055), between RAI-CROMRIS and presence of elevated erythrocyte sedimentation rate (p = 0.013) and C-reactive protein (p = 0.0001) at baseline. The RAI-CROMRIS decreased from a median of 17 at baseline to 12 at 6 months (p = 0.004) and remained stable (median 11) at 12 months. A correlation between the RAI-CROMRIS and the PGA was observed at baseline (rs = 0.41; p = 0.004) and during follow up at 6 months (rs = 0.33; p = 0.025) and 12 months (rs = 0.38; p = 0.010). The baseline RAI-CROMRIS (median 20) was significantly higher in patients who subsequently received bisphosphonates than in patients who received other treatments (median 12) and decreased significantly after bisphosphonates (p = 0.008). CONCLUSIONS: The RAI-CROMRIS was correlated with clinical and laboratory measures of disease activity showing significant short-term changes following treatment with bisphosphonates. This tool could be used in clinical practice and clinical trials after validation.

Layered enhancement at magnetic resonance enterography in inflammatory bowel disease: A meta-analysis.

BACKGROUND: Documentation of disease activity in patients affected by Crohn's disease (CD) is mandatory in order to manage patients properly. Magnetic resonance imaging (MRI) is considered the reference cross-sectional technique for the assessment of CD activity. Among MRI findings, layered pattern (LP) of contrast enhancement seems to be one of the most significant signs of severe disease activity; however, it has also been associated with chronic disease and mural fibrosis. AIM: To systematically evaluate the accuracy of LP of contrast enhancement in the diagnosis of active inflammation in patients with CD. METHODS: In February 2019, we searched the MEDLINE and Cochrane Central Register of Controlled Trials databases for studies evaluating the diagnostic accuracy of LP of contrast enhancement on MRI for the detection of active inflammation in patients with CD. To be included, studies had to use histopathologic analysis (endoscopy or surgery) as the reference standard. Risk of bias and applicability concerns of the included studies were evaluated by using items from the Quality Assessment for Diagnostic Accuracy Studies 2 (QUADAS-2) tool. Pooled sensitivity and specificity were determined using a bivariate random-effect model. Heterogeneity was quantified by using the I 2 statistic. Our meta-analysis received no funding, and the review protocol was not published or registered in advance. RESULTS: Of the 1383 studies identified, five articles were finally selected for quantitative and qualitative synthesis (245 patients, 238 of whom had histopathologically confirmed CD, 144 with active inflammation and 94 with inactive disease). The meta-analysis showed a pooled sensitivity of 49.3% (95%CI: 41%-57.8%; I 2: 90.7%) and specificity of 89.1% (95%CI: 81.3%- 94.4%; I 2: 48.6%). Pooled PLR and NLR were 3.3 (95%CI: 1.9-5.7; I 2: 6.1%) and 0.6 (95%CI: 0.5-0.9; I 2 70.5%), respectively. SDOR was 6.8 (95%CI: 2.6-17.6; I 2: 27.1%). The summary ROC curve showed an area under the curve (AUC) of 0.82 (SE 0.06; Q* 0.76). High risk of bias and applicability concerns were observed in the domains of patient selection for one included study. CONCLUSION: LP on contrast-enhanced MRI is a specific finding to rule out active inflammation in patients with CD. Further studies using a prespecified definition of LP on contrast-enhanced MRI are needed to support our findings.

Severe chest allodynia as an unusual first presentation of hydatid disease: a case report.

BACKGROUND: Cystic echinococcosis (CE) is a worldwide zoonosis and the liver is the most commonly affected organ. Clinical manifestations range from completely asymptomatic cysts to a potential lethal cyst rupture and anaphylaxis. CASE PRESENTATION: Severe chest allodynia was an unusual clinical presentation of hepatic cyst rupture in the retroperitoneal space, without any other specific symptoms. CE diagnosis was confirmed by computed tomography scan and magnetic resonance. The patient underwent hepatectomy with complete resolution of the neuropathic pain. CONCLUSIONS: Retroperitoneal hydatid cyst rupture is a rare event and its clinical manifestation may mimic other chest neuropathies.

Half-dose Coronary Artery Calcium Scoring: Impact of Iterative Reconstruction.

PURPOSE: The purpose of this study was to assess the impact of adaptive statistical iterative reconstruction (ASiR) on half-dose coronary artery calcium scoring (CACS) acquisition protocol. MATERIALS AND METHODS: Between September 2016 and October 2017, 89 patients (54 male patients, mean age 64.6±10.7 y) with a clinically indicated coronary computed tomography angiography were prospectively enrolled. On a 64-row computed tomography scanner, patients underwent a standard CACS protocol (120 kVp, 170 mAs) reconstructed by filtered-back projection, and a half-dose CACS protocol (120 kVp, 85 mAs) reconstructed by ASiR at different percentages, from 10% to 100%, in 10% increments. CACS determinants (Agatston score, number of plaques, volume, and mass), signal-to-noise ratio, contrast-to-noise ratio, and radiation dose of both protocols were calculated. Patient risk categories based on CACS were determined for each protocol, and analysis of risk reclassification of half-dose protocol was performed. Depending on their body mass index (BMI), patients were divided into nonobese (BMI<30 kg/m) and obese (BMI≥30 kg/m) groups to investigate the influence of BMI on CACS determinants and risk reclassification. RESULTS: Half-dose protocol reconstructed with ASiR 70% showed no significant differences in any CACS determinant compared with the standard protocol for both nonobese and obese patients (all P≥0.070 and ≥0.066, respectively) and reclassified 1 (1.7%) and 6 (20.0%) patients, respectively, with excellent (κ=0.91) and good (κ=0.74) agreement with standard protocol, respectively. ASiR 70% also resulted in a higher signal-to-noise ratio (1.88±0.78) and contrast-to-noise ratio (7.10±2.73) compared with standard protocol (all P≤0.001). Half-dose protocol provided 52% less radiation dose than standard acquisition (0.31±0.06 vs. 0.64±0.10 mSv; P<0.001). CONCLUSIONS: ASIR 70% coupled with reduction of tube current by 50% allowed for significant dose reduction and no detrimental effects on image quality, with minimal patient reclassification in nonobese patients. In obese patients, excessive noise may lead to a clinically significant reclassification rate.

Lean Body Weight-Tailored Iodinated Contrast Injection in Obese Patient: Boer versus James Formula.

PURPOSE: To prospectively compare the performance of James and Boer formula in contrast media (CM) administration, in terms of image quality and parenchymal enhancement in obese patients undergoing CT of the abdomen. MATERIALS AND METHODS: Fifty-five patients with a body mass index (BMI) greater than 35 kg/m2 were prospectively included in the study. All patients underwent 64-row CT examination and were randomly divided in two groups: 26 patients in Group A and 29 patients in Group B. The amount of injected CM was computed according to the patient's lean body weight (LBW), estimated using either Boer formula (Group A) or James formula (Group B). Patient's characteristics, CM volume, contrast-to-noise ratio (CNR) of liver, aorta and portal vein, and liver contrast enhancement index (CEI) were compared between the two groups. For subjective image analysis readers were asked to rate the enhancement of liver, kidneys, and pancreas based on a 5-point Likert scale. RESULTS: Liver CNR, aortic CNR, and portal vein CNR showed no significant difference between Group A and Group B (all P ≥ 0.177). Group A provided significantly higher CEI compared to Group B (P = 0.007). Group A and Group B returned comparable overall subjective enhancement values (3.54 and vs 3.20, all P ≥ 0.199). CONCLUSIONS: Boer formula should be the method of choice for LBW estimation in obese patients, leading to an accurate CM amount calculation and an optimal liver contrast enhancement in CT.